July 25, 2018
A shift in focus: Lorson moves basic research to drug development
By Roger Meissen & Erica Overfelt | Bond LSC It takes a lot to move a discovery from lab bench to an application that can provide therapeutic benefits to those suffering from disease. Bond LSC’s Chris Lorson is making moves to bridge that gap with the start of Shift Pharmaceuticals. With its formation in March 2017, Lorson adds co-founder and Chief Science Officer of the company to his list of titles that include Bond LSC investigator, professor of veterinary pathobiology and associate dean for research and graduate studies. Shift Pharmaceuticals builds off of years of progress the Lorson Lab has…
